Onconetix Inc (ONCO)

$0.62 +0.14 (28.39%)
Market Cap 806,000.00
Revenue (ttm) 820,000.00
Net Income (ttm) -14.03M
EPS (ttm) N/A
PE Ratio 0.02
Forward PE N/A
Profit Margin -1,710.98%
Debt to Equity Ratio 0.00
Volume 147,600
Avg Vol 388,012
Day's Range N/A - N/A
Shares Out 1.56M
Stochastic %K 90%
Beta 3.51
Analysts Strong Buy
Price Target N/A

Company Profile

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, I...

Industry: Biotechnology
Sector: Healthcare
Phone: 513 620 4101
Address:
201 East Fifth Street, Suite 1900, Cincinnati, United States
DELETE26
DELETE26 Mar. 21 at 8:02 PM
$JAGU $ONCO $CMBM $WATT $MNDR He's using gas and a rifle to go up +20, then closing it in the negative. Jagu is posting every day. A group... I wonder what you got caught at 🤣
0 · Reply
StrykerTactics
StrykerTactics Mar. 21 at 5:48 PM
$JAGU Lot of upcoming catalyst ahead, and there's a chance they can even get a gov contract, how big would that be? Pretty big! Uranium/rare earth is a hot sector right now. . $ONCO $CMBM $WATT $MNDR
0 · Reply
MrGMac
MrGMac Mar. 21 at 4:15 AM
$ONCO well that was some impressive paper hands after hours….
0 · Reply
ka1954
ka1954 Mar. 20 at 8:04 PM
$ONCO who is going to take this to $4? nobody
0 · Reply
foodandgold
foodandgold Mar. 20 at 1:26 PM
$ONCO this is a $4 stock
0 · Reply
MrGMac
MrGMac Mar. 20 at 10:31 AM
$ONCO correct
0 · Reply
ka1954
ka1954 Mar. 19 at 4:55 PM
$ONCO fuckers, stop selling ur shit
0 · Reply
Livinglifewithlivingston
Livinglifewithlivingston Mar. 19 at 4:53 PM
$ONCO just started a position
0 · Reply
MrGMac
MrGMac Mar. 19 at 3:33 PM
$ONCO lol
0 · Reply
RzrBck2005
RzrBck2005 Mar. 19 at 1:56 PM
$ONCO
0 · Reply
Latest News on ONCO
Onconetix to Acquire Realbotix LLC, USA-based, AI-Powered Humanoid Robotics Company

Feb 12, 2026, 8:00 AM EST - 5 weeks ago

Onconetix to Acquire Realbotix LLC, USA-based, AI-Powered Humanoid Robotics Company

Realbotix Corp. Announces the Sale of Realbotix, LLC Subsidiary to a NASDAQ Listed Issuer

Feb 12, 2026, 8:00 AM EST - 5 weeks ago

Realbotix Corp. Announces the Sale of Realbotix, LLC Subsidiary to a NASDAQ Listed Issuer

Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc.

Sep 26, 2025, 8:30 AM EDT - 6 months ago

Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc.

Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement

Sep 26, 2025, 8:15 AM EDT - 6 months ago

Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement

Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM

Sep 22, 2025, 8:00 AM EDT - 6 months ago

Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM

Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement

Jul 16, 2025, 8:17 AM EDT - 8 months ago

Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement

Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel

Jun 16, 2025, 8:22 AM EDT - 9 months ago

Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel

Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders

Jun 11, 2025, 11:30 AM EDT - 10 months ago

Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders

Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq

May 22, 2025, 4:50 PM EDT - 10 months ago

Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq

Onco-Innovations Uplists to Cboe Canada

May 22, 2025, 10:00 AM EDT - 10 months ago

Onco-Innovations Uplists to Cboe Canada

Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort

Mar 24, 2025, 8:45 AM EDT - 1 year ago

Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort

Onconetix Announces New Clinical Data for its Innovative Prostate Cancer Test Proclarix Accepted for Presentation at 2025 European Association of Urology Congress

Mar 19, 2025, 8:00 AM EDT - 1 year ago

Onconetix Announces New Clinical Data for its Innovative Prostate Cancer Test Proclarix Accepted for Presentation at 2025 European Association of Urology Congress

Onconetix, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q and Subsequent Filing

Dec 12, 2024, 5:00 PM EST - 1 year ago

Onconetix, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q and Subsequent Filing

Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

Oct 8, 2024, 5:00 AM EDT - 1 year ago

Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

OCS VRNA GRDX

Correction: Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit

Oct 3, 2024, 4:45 PM EDT - 1 year ago

Correction: Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit

Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit

Oct 3, 2024, 9:05 AM EDT - 1 year ago

Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit

Crude Oil Rises; Onconetix Shares Spike Higher

Sep 27, 2024, 2:41 PM EDT - 1 year ago

Crude Oil Rises; Onconetix Shares Spike Higher

Onconetix, Inc. Announces 1-for-40 Reverse Stock Split and Results of the Annual Meeting of Stockholders

Sep 20, 2024, 11:45 AM EDT - 1 year ago

Onconetix, Inc. Announces 1-for-40 Reverse Stock Split and Results of the Annual Meeting of Stockholders

Onconetix Announces Closing of Warrant Exercise for $1.11 Million Gross Proceeds

Jul 15, 2024, 6:00 AM EDT - 1 year ago

Onconetix Announces Closing of Warrant Exercise for $1.11 Million Gross Proceeds

Onconetix Announces Exercise of Warrants for $1.11 Million Gross Proceeds

Jul 11, 2024, 8:17 AM EDT - 1 year ago

Onconetix Announces Exercise of Warrants for $1.11 Million Gross Proceeds

Onconetix Announces Appointment of Seasoned Biotech Executives Dr. Ajit Singh and Dr. Thomas Meier to Its Board of Directors

Feb 13, 2024, 6:00 AM EST - 2 years ago

Onconetix Announces Appointment of Seasoned Biotech Executives Dr. Ajit Singh and Dr. Thomas Meier to Its Board of Directors

Onconetix™ Chief Executive Officer Dr. Neil J. Campbell Issues Letter to Shareholders

Dec 19, 2023, 7:00 AM EST - 2 years ago

Onconetix™ Chief Executive Officer Dr. Neil J. Campbell Issues Letter to Shareholders

Blue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name Change to Onconetix™

Dec 18, 2023, 7:00 AM EST - 2 years ago

Blue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name Change to Onconetix™

Blue Water Biotech Signs Non-Binding Term Sheet to Acquire a Commercial Stage Oncology Company

Nov 2, 2023, 7:00 AM EDT - 2 years ago

Blue Water Biotech Signs Non-Binding Term Sheet to Acquire a Commercial Stage Oncology Company

Blue Water Biotech Announces It Has Regained Compliance with Nasdaq Listing Rule 5250(c)(1)

Nov 1, 2023, 7:00 AM EDT - 2 years ago

Blue Water Biotech Announces It Has Regained Compliance with Nasdaq Listing Rule 5250(c)(1)

Blue Water Biotech Issues Letter to Shareholders

Oct 30, 2023, 7:00 AM EDT - 2 years ago

Blue Water Biotech Issues Letter to Shareholders

Blue Water Biotech Appoints Dr. Neil J. Campbell as President and CEO and Bruce Harmon as CFO

Oct 10, 2023, 9:00 AM EDT - 2 years ago

Blue Water Biotech Appoints Dr. Neil J. Campbell as President and CEO and Bruce Harmon as CFO

Blue Water Biotech, Inc. Announces Notification From Nasdaq Related to Delayed Quarterly Report on Form 10-Q

Aug 28, 2023, 4:30 PM EDT - 2 years ago

Blue Water Biotech, Inc. Announces Notification From Nasdaq Related to Delayed Quarterly Report on Form 10-Q

Blue Water Biotech Announces Closing of Warrant Exercise and Issuance of New Warrants in A Private Placement For $2.7 Million Gross Proceeds

Aug 3, 2023, 1:02 PM EDT - 2 years ago

Blue Water Biotech Announces Closing of Warrant Exercise and Issuance of New Warrants in A Private Placement For $2.7 Million Gross Proceeds

Blue Water Biotech Announces Exercise of Warrants and Issuance of New Warrants in A Private Placement For $2.7 Million Gross Proceeds

Aug 1, 2023, 8:00 AM EDT - 2 years ago

Blue Water Biotech Announces Exercise of Warrants and Issuance of New Warrants in A Private Placement For $2.7 Million Gross Proceeds

Blue Water Biotech and Knipper Health Join Forces to Distribute Samples for ENTADFI® and ZONTIVITY® to Physicians

Jul 31, 2023, 9:00 AM EDT - 2 years ago

Blue Water Biotech and Knipper Health Join Forces to Distribute Samples for ENTADFI® and ZONTIVITY® to Physicians

Blue Water Biotech Teams with UpScriptHealth to Launch Telemedicine Platform for Benign Prostatic Hyperplasia Asset, ENTADFI®

Jul 25, 2023, 9:00 AM EDT - 2 years ago

Blue Water Biotech Teams with UpScriptHealth to Launch Telemedicine Platform for Benign Prostatic Hyperplasia Asset, ENTADFI®

Blue Water Biotech Issues CEO Shareholder Letter Providing Update on Commercial Launch Activities

Jul 17, 2023, 9:00 AM EDT - 2 years ago

Blue Water Biotech Issues CEO Shareholder Letter Providing Update on Commercial Launch Activities

Blue Water Biotech Teams with Advantage Point Solutions to Provide Healthcare Payer Coverage Support

Jul 11, 2023, 9:00 AM EDT - 2 years ago

Blue Water Biotech Teams with Advantage Point Solutions to Provide Healthcare Payer Coverage Support

Blue Water Biotech Secures License from Ohio State Board of Pharmacy to Operate as Pharmaceutical Wholesaler for its FDA Approved Products

Jul 6, 2023, 5:05 PM EDT - 2 years ago

Blue Water Biotech Secures License from Ohio State Board of Pharmacy to Operate as Pharmaceutical Wholesaler for its FDA Approved Products

Blue Water Biotech Teams with BFW Advertising to Market and Advertise Commercial Product Portfolio

Jul 6, 2023, 7:30 AM EDT - 2 years ago

Blue Water Biotech Teams with BFW Advertising to Market and Advertise Commercial Product Portfolio

Blue Water Biotech Announces Preclinical Data Supporting Immunogenicity of Novel Monkeypox Vaccine Utilizing Norovirus Virus-Like Particle Platform

Jun 28, 2023, 7:55 AM EDT - 2 years ago

Blue Water Biotech Announces Preclinical Data Supporting Immunogenicity of Novel Monkeypox Vaccine Utilizing Norovirus Virus-Like Particle Platform

Blue Water Biotech Collaborates with IQVIA to Build Medical Sales Representative Team to Market Commercial Product Portfolio

Jun 21, 2023, 7:30 AM EDT - 2 years ago

Blue Water Biotech Collaborates with IQVIA to Build Medical Sales Representative Team to Market Commercial Product Portfolio

Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas

Jun 14, 2023, 7:30 AM EDT - 3 years ago

Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas

Blue Water Biotech Reports First Quarter 2023 Financial Results and Recent Business Highlights

May 12, 2023, 6:32 PM EDT - 3 years ago

Blue Water Biotech Reports First Quarter 2023 Financial Results and Recent Business Highlights

Blue Water Biotech to Present Corporate Overview and ENTADFI® Launch Plan at the JMP Securities Life Sciences Conference in New York, NY

May 10, 2023, 12:15 PM EDT - 3 years ago

Blue Water Biotech to Present Corporate Overview and ENTADFI® Launch Plan at the JMP Securities Life Sciences Conference in New York, NY

Blue Water Biotech Appoints Board-Certified Urologist Jay Newmark, M.D., MBA as Chief Medical Officer

Apr 26, 2023, 3:44 PM EDT - 3 years ago

Blue Water Biotech Appoints Board-Certified Urologist Jay Newmark, M.D., MBA as Chief Medical Officer

Blue Water Biotech to Participate in the American Urological Association Annual Meeting 2023 to Promote Benign Prostatic Hyperplasia Treatment ENTADFI®

Apr 25, 2023, 8:00 AM EDT - 3 years ago

Blue Water Biotech to Participate in the American Urological Association Annual Meeting 2023 to Promote Benign Prostatic Hyperplasia Treatment ENTADFI®

Blue Water Vaccines Announces Corporate Name Change to Blue Water Biotech in Connection with Transition into Commercial-Stage Biotechnology Company

Apr 24, 2023, 8:00 AM EDT - 3 years ago

Blue Water Vaccines Announces Corporate Name Change to Blue Water Biotech in Connection with Transition into Commercial-Stage Biotechnology Company

Blue Water Announces Acquisition of ENTADFI®, an FDA-Approved Benign Prostatic Hyperplasia Asset

Apr 20, 2023, 7:30 AM EDT - 3 years ago

Blue Water Announces Acquisition of ENTADFI®, an FDA-Approved Benign Prostatic Hyperplasia Asset

Blue Water Vaccines Announces Signing of Sponsored Research Agreement with The University of Texas Health Science Center at San Antonio to Initiate Non-Human Primate Study for Live Attenuated, Orally Delivered Chlamydia Vaccine

Apr 12, 2023, 8:30 AM EDT - 3 years ago

Blue Water Vaccines Announces Signing of Sponsored Research Agreement with The University of Texas Health Science Center at San Antonio to Initiate Non-Human Primate Study for Live Attenuated, Orally Delivered Chlamydia Vaccine

Blue Water Vaccines Reports Year 2022 Financial Results and Recent Business Highlights

Mar 9, 2023, 8:30 AM EST - 3 years ago

Blue Water Vaccines Reports Year 2022 Financial Results and Recent Business Highlights

Blue Water Vaccines Appoints Seasoned Commercial Operations Leader Frank Jaeger as Senior Vice President of Marketing and Business Development

Feb 6, 2023, 10:15 AM EST - 3 years ago

Blue Water Vaccines Appoints Seasoned Commercial Operations Leader Frank Jaeger as Senior Vice President of Marketing and Business Development

Blue Water Vaccines Announces Partnership with AbVacc for Joint Development of Novel Monkeypox and Marburg Vaccine Candidates

Feb 1, 2023, 9:15 AM EST - 3 years ago

Blue Water Vaccines Announces Partnership with AbVacc for Joint Development of Novel Monkeypox and Marburg Vaccine Candidates

DELETE26
DELETE26 Mar. 21 at 8:02 PM
$JAGU $ONCO $CMBM $WATT $MNDR He's using gas and a rifle to go up +20, then closing it in the negative. Jagu is posting every day. A group... I wonder what you got caught at 🤣
0 · Reply
StrykerTactics
StrykerTactics Mar. 21 at 5:48 PM
$JAGU Lot of upcoming catalyst ahead, and there's a chance they can even get a gov contract, how big would that be? Pretty big! Uranium/rare earth is a hot sector right now. . $ONCO $CMBM $WATT $MNDR
0 · Reply
MrGMac
MrGMac Mar. 21 at 4:15 AM
$ONCO well that was some impressive paper hands after hours….
0 · Reply
ka1954
ka1954 Mar. 20 at 8:04 PM
$ONCO who is going to take this to $4? nobody
0 · Reply
foodandgold
foodandgold Mar. 20 at 1:26 PM
$ONCO this is a $4 stock
0 · Reply
MrGMac
MrGMac Mar. 20 at 10:31 AM
$ONCO correct
0 · Reply
ka1954
ka1954 Mar. 19 at 4:55 PM
$ONCO fuckers, stop selling ur shit
0 · Reply
Livinglifewithlivingston
Livinglifewithlivingston Mar. 19 at 4:53 PM
$ONCO just started a position
0 · Reply
MrGMac
MrGMac Mar. 19 at 3:33 PM
$ONCO lol
0 · Reply
RzrBck2005
RzrBck2005 Mar. 19 at 1:56 PM
$ONCO
0 · Reply
RzrBck2005
RzrBck2005 Mar. 18 at 9:36 PM
$ONCO
0 · Reply
Erog24
Erog24 Mar. 18 at 7:57 PM
$ONCO let’s keep this thing active. It could pop any day
1 · Reply
Take_wins
Take_wins Mar. 18 at 1:22 PM
$ONCO Realbotix’s agreement with $ONCO introduces an alternative pathway to #NASDAQ. CEO Andrew Kiguel explains how the proposed transaction is structured and what it could mean for shareholders. Watch the full interview: http://ordnl.link/y8fHw4n 🇨🇦 #TSXV: $XBOT $XBOT.V 🇺🇸 #OTCQB: $XBOTF #takeoverstrategy #AI #robots
1 · Reply
SwissGerald
SwissGerald Mar. 18 at 1:09 AM
$XBOTF I'm really not familiar with penny stock stuff, but here's a silly question: If they had done the $ONCO deal as a spin-off, like $XBOTF shareholders receiving two (for example) new shares of the new Nasdaq-listed company for each existing share... wouldn't that have been better so we could benefit more directly from the new subsidiary? 🤔
2 · Reply
MrGMac
MrGMac Mar. 17 at 1:42 PM
$ONCO
0 · Reply
RzrBck2005
RzrBck2005 Mar. 17 at 12:16 PM
$ONCO
0 · Reply
Take_wins
Take_wins Mar. 16 at 5:35 PM
$ONCO bleeding
0 · Reply
MrGMac
MrGMac Mar. 16 at 1:23 PM
$ONCO this will rip with even some low volume….. let’s go
0 · Reply
ChartChartist
ChartChartist Mar. 15 at 9:28 PM
$SPHL ready for $12? $FRGT load here $ONCO moon will take it again to $1 $ABTS great setup All these 1mil floats look amazing $AEHL is first. This week, then the next ones ; aehl is the play
1 · Reply
Take_wins
Take_wins Mar. 13 at 7:11 PM
$ONCO
0 · Reply
MrGMac
MrGMac Mar. 13 at 4:45 AM
$ONCO wtf… 😳
0 · Reply
MrGMac
MrGMac Mar. 12 at 1:36 PM
$ONCO
0 · Reply